bioAffinity Technologies, Inc.
BIAF
$2.96
-$0.29-8.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.68M | 8.81M | 9.36M | 9.37M | 7.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.68M | 8.81M | 9.36M | 9.37M | 7.32M |
| Cost of Revenue | 5.39M | 5.78M | 5.98M | 6.09M | 4.72M |
| Gross Profit | 2.29M | 3.03M | 3.38M | 3.28M | 2.60M |
| SG&A Expenses | 9.95M | 10.21M | 9.94M | 9.24M | 8.90M |
| Depreciation & Amortization | 572.70K | 610.60K | 605.60K | 600.80K | 507.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.74M | 18.44M | 18.32M | 17.72M | 15.99M |
| Operating Income | -10.06M | -9.64M | -8.95M | -8.35M | -8.67M |
| Income Before Tax | -11.65M | -9.72M | -9.03M | -8.43M | -8.72M |
| Income Tax Expenses | 40.30K | 16.70K | 11.70K | 14.00K | 13.70K |
| Earnings from Continuing Operations | -11.69 | -9.74 | -9.04 | -8.45 | -8.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.69M | -9.74M | -9.04M | -8.45M | -8.74M |
| EBIT | -10.06M | -9.64M | -8.95M | -8.35M | -8.67M |
| EBITDA | -9.49M | -9.02M | -8.35M | -7.75M | -8.16M |
| EPS Basic | -20.84 | -21.33 | -22.36 | -23.96 | -27.02 |
| Normalized Basic EPS | -12.99 | -13.31 | -13.95 | -14.95 | -16.86 |
| EPS Diluted | -20.84 | -21.33 | -22.36 | -23.96 | -27.02 |
| Normalized Diluted EPS | -12.99 | -13.31 | -13.95 | -14.95 | -16.86 |
| Average Basic Shares Outstanding | 2.25M | 1.83M | 1.62M | 1.43M | 1.31M |
| Average Diluted Shares Outstanding | 2.25M | 1.83M | 1.62M | 1.43M | 1.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |